| Date Filed | Type | Description |
| 08/15/2023 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 22,620 shares
@ $0
Paid exercise price by delivering 11,215 shares
@ $18.91, valued at
$212.1k
|
|
| 07/05/2023 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 769 shares
@ $15.606, valued at
$12k
Sold 1,701 shares
@ $25.04, valued at
$42.6k
|
|
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/05/2023 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Sold 2,701 shares
@ $30.57, valued at
$82.6k
Sold 500 shares
@ $31, valued at
$15.5k
|
|
| 06/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/16/2023 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 42,349 shares
@ $0
Sold 21,401 shares
@ $34.5469, valued at
$739.3k
|
|
| 05/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/04/2023 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Sold 3,201 shares
@ $32.15, valued at
$102.9k
|
|
| 03/17/2023 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 3,739 shares
@ $30.65, valued at
$114.6k
|
|
| 03/09/2023 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 42,349 shares
@ $0
Sold 18,517 shares
@ $31.5863, valued at
$584.9k
|
|
| 03/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/02/2023 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Sold 3,201 shares
@ $33.5, valued at
$107.2k
|
|
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/23/2023 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Sold 1,000 shares
@ $31, valued at
$31k
|
|
| 01/10/2023 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Sold 1,701 shares
@ $25, valued at
$42.5k
Sold 1,000 shares
@ $28, valued at
$28k
Sold 1,000 shares
@ $30, valued at
$30k
|
|
| 01/03/2023 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 645 shares
@ $12.1805, valued at
$7.9k
|
|
| 12/16/2022 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,557 shares
@ $21.5, valued at
$33.5k
|
|
| 07/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/17/2022 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 2,241 shares
@ $13.35, valued at
$29.9k
Paid exercise price by delivering 683 shares
@ $13.35, valued at
$9.1k
|
|
| 02/04/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/04/2022 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Acquired 404 shares
@ $13.872, valued at
$5.6k
|
|
| 12/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/19/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/22/2020 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,556 shares
@ $26.75, valued at
$41.6k
|
|
| 10/02/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/02/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/19/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/24/2020 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 16,500 shares
@ $0
Granted 97,500 options to buy
@ $22.32, valued at
$2.2M
|
|
|